7 DECember 2023

BIOPHARMA CREDIT PLC

(THE "COMPANY")

Publication of Circular and Notice of General Meeting

Further to the announcement on 1 November 2023, the Company today announces that it has published a shareholder circular (the "Circular") and notice of general meeting (the "General Meeting") for the purpose of proposing a vote in relation to the continuation of the Company (the "Proposals"). The detailed reasons for and background to the Proposals are set out in the Circular.

The Board unanimously recommends that Shareholders vote in favour of the Continuation Resolution.

The Continuation Resolution must be passed by a majority of at least half of the votes of the Shareholders entitled to vote and voting, whether in person or by proxy, at the General Meeting. If the Continuation Resolution is passed by Shareholders at the General Meeting, the Directors will be required to put a further continuation resolution to Shareholders no later than the Company's annual general meeting in 2025, in accordance with Article 152(1).

If the Continuation Resolution is not passed by Shareholders at the General Meeting, then, under the Articles, the Directors shall be required, within six months of the resolution not being passed, to put proposals to the Shareholders for the reconstruction, reorganisation or winding up of the Company.

The General Meeting will be held at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG at 10 a.m. on 28 December 2023.

The Circular will be posted to Shareholders today and a copy of the Circular can be found on the Company's website at http://www.bpcruk.com. A copy of the Circular has also been submitted to the National Storage Mechanism and will shortly be available for viewing online at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Terms used in this announcement unless otherwise defined, shall have the same meaning as set out in the Circular.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0) 333 300 1950

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24